Lv1
30 积分 2025-03-20 加入
Real-Word Effectiveness of Early Start-Up and Short-Term Use of PCSK9 Inhibitor in the Treatment of Acute Coronary Syndrome in China
1个月前
已完结
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
2个月前
已关闭
Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
2个月前
已完结
PCSK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis
2个月前
已完结
Impact of PCSK9 inhibitors on bleeding and adverse outcomes in post-PCI patients undergoing antiplatelet therapy: A real-world cohort study
2个月前
已完结
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial
2个月前
已完结
Effectiveness and safety of long‐term therapy with alirocumab in acute coronary syndrome patients: A single‐centre retrospective real‐world study
2个月前
已完结
Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España
2个月前
已完结
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
2个月前
已完结
The Experience of Using the Drug Inclusiran in Patients With an Extremely High Risk Of Developing Cardiovascular Complications in The Acute Period of Myocardial Infarction
2个月前
已完结
皖公网安备34019202002308
